Complex chronic adverse events following immunization: a systemic critique and reform proposal for vaccine pharmacovigilance.
Kenny, Tiff-Annie · Therapeutic advances in drug safety · 2025 · DOI
Quick Summary
This paper describes complex, long-lasting health problems that some people develop after vaccination, which resemble ME/CFS and Long COVID symptoms like fatigue, pain, brain fog, and heart rhythm issues. The author argues that current vaccine safety systems are not well-designed to detect or investigate these kinds of slow-developing, multisystem conditions because they work best for identifying immediate reactions like fever or allergies. The paper proposes changes to how we monitor vaccine safety—including better training for doctors, longer-term tracking of patients, and including patients' own descriptions of their symptoms—to catch these problems more effectively.
Why It Matters
This work is critical for ME/CFS because it formally articulates why patients with complex post-infectious and post-vaccination syndromes are systematically missed by existing safety systems, and proposes structural reforms to improve recognition and investigation. For researchers, it provides a conceptual framework (CC-AEFIs) that acknowledges symptom heterogeneity, delayed onset, and multisystem involvement—features central to ME/CFS—and advocates for longitudinal, patient-centered data collection. By highlighting shared mechanisms between post-vaccination and post-infectious syndromes, it strengthens the rationale for integrated investigation of immune-mediated chronic conditions.
Observed Findings
Current vaccine safety systems are optimized for detecting acute, well-defined adverse events (e.g., fever, allergic reactions) and fail to systematically capture persistent, multisystem conditions with delayed onset and fluctuating trajectories.
Complex chronic presentations following immunization often involve dysautonomia, neuropathic pain, post-exertional malaise, and cognitive dysfunction—symptoms overlapping with both ME/CFS and Long COVID.
Patients reporting complex chronic post-vaccination symptoms frequently experience dismissal, underdiagnosis, and misattribution to psychological causes due to lack of objective biomarkers and diagnostic ambiguity.
Pharmacovigi lance governance structures lack transparency, are influenced by vaccine manufacturers, and rarely include patient perspectives or longitudinal outcome data.
Existing pharmacovigilance definitions and tools systematically exclude complex, delayed, or multifactorial conditions from formal adverse event classification and analysis.
Inferred Conclusions
Vaccine safety systems require fundamental structural reform to detect and investigate rare, complex chronic conditions that challenge conventional diagnostic and epidemiological paradigms.
Enhanced clinician education, longitudinal patient-centered surveillance, integration of patient-reported outcomes, and transparent governance with patient participation are necessary to improve responsiveness to complex chronic adverse events.
Shared mechanistic pathways may exist between post-infectious syndromes (including Long COVID) and post-vaccination complex chronic presentations, warranting integrated investigative approaches.
What This Study Does Not Prove
This paper does not establish causality between vaccination and any specific chronic illness, nor does it quantify the incidence or prevalence of CC-AEFIs in the population. It is a qualitative systems analysis and reform proposal, not an epidemiological or mechanistic study; therefore, it cannot prove that vaccination causes ME/CFS-like syndromes, only that current systems fail to adequately investigate such cases when reported. The framework is descriptive and surveillance-oriented, not explanatory of underlying biology.
Current system limitations represent both scientific gaps (inability to detect rare patterns) and epistemic gaps (exclusion of patient knowledge and lived experience) that undermine trust and equitable care.
Remaining Questions
What are the actual incidence and prevalence of CC-AEFIs following different vaccines, and how do these compare to background rates in unvaccinated populations?
What are the specific immune mechanisms linking post-vaccination and post-infectious complex syndromes, and are they identical across different triggering events (e.g., SARS-CoV-2 infection vs. vaccination)?
How should longitudinal surveillance systems be designed to balance signal detection with the inherent diagnostic and symptom heterogeneity of complex chronic conditions?
What patient-centered outcome measures should be incorporated into pharmacovigilance to capture the full burden of CC-AEFIs and ensure equitable recognition across diverse populations?